Fifty 1 Labs and UAV Corp to Host Virtual Shareholder Teleconference with Nobel Laureate Dr. James Orbinski

Fifty 1 Labs, Inc. (OTC: FITY), in partnership with UAV Corp (OTC: UMAV), is organizing a virtual shareholder teleconference scheduled for July 28, 2025, at 12:00 PM EST. The event will be highlighted by the participation of Nobel Laureate Dr. James Orbinski, known for his humanitarian work and acceptance of the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières. The teleconference will be broadcast live on X (formerly Twitter), offering a platform for Fifty 1 Labs to share its strategic initiatives, particularly in the realm of AI-driven drug repurposing for functional medicine, alongside discussions on significant R&D investments and future biotech acquisitions.

Dr. Orbinski's involvement is a testament to the potential global health implications of Fifty 1 Labs' projects. The company's CEO, Paul Arora, is set to outline the firm's dedication to pioneering health and wellness innovations, with a special emphasis on off-patent drug repurposing and adaptive clinical trials. This strategy not only underscores the company's growth trajectory but also reflects its alignment with shareholder interests, as demonstrated by management's personal investments and the deferral of salaries until specific milestones are reached.

This teleconference marks a critical juncture for Fifty 1 Labs as it aims to strengthen its foothold in the biotech and wellness industries. The collaboration with UAV Corp and the insights from Dr. Orbinski are expected to shed light on the transformative potential of Fifty 1 Labs' approach to healthcare innovation. For more information, visit https://ibn.fm/vdzmf.